AbbVie said its Board of Directors approved an amendment and restatement of the company's bylaws, the Third Amended and Restated By-laws, on September 6, 2024, and that they took effect the same day.

1. 01

   AbbVie said its Board of Directors approved an amendment and restatement of the company's bylaws, the Third Amended and Restated By-laws, on September 6, 2024, and that they took effect the same day.

2. 02

   The company said the amendments (1) update the address of the company's registered agent and (2) delete Section 2.13(D)(iv) in its entirety.

3. 03

   The company said it is the defendant in a stockholder class action challenging the lawfulness of Section 2.13(D)(iv). It said it believes the provision is lawful but no longer has any practical value.

4. 04

   The company said it does not believe defending this provision is the best use of company resources. The full text of the amended bylaws is attached as Exhibit 3.1 to this 8-K.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.